Friedenson [14] has summarized these reports, analyzing data from more than 30 epidemiological studies on the incidence of other than the breast or ovarian cancers in BRCA1 and BRCA2 mutation carriers and in large populations eligible for mutation testing. This evidence concerns the gene BRCA2 and ovarian cancer.